17 March 2022BiotechDonald McNab and Mark Schuster
The fall of COVID-19 and the rise of antimicrobial resistance
At the time of writing, the nations of the UK are in the process of abandoning or at least easing, the legal restrictions introduced during the COVID-19 pandemic. So, it appears that this crisis is reaching—if not an end—the end of the beginning. For the past two years, the pandemic has dominated the public scientific conversation, with enormous amounts of public and private resources being directed to its resolution.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 November 2026 A US judge tosses an antitrust lawsuit accusing Alexion of using sham patent litigation to delay competition to Soliris, finding that its favourable settlement with a rival undermined the claims.
16 November 2026 The Swiss pharma giant will work with a Taiwan-based biotech’s ADC platform technologies to develop next-generation cancer therapies in a deal worth potentially more than $2bn, including $30m upfront.
13 November 2026 Curiox claims confidential information shared during talks about a potential business partnership was used to develop a competing cell preparation system within months, despite the South Korean company spending years developing its own technology.